A multiparameter approach to monitor disease activity in collagen-induced arthritis

Arthritis Research and Therapy

Volumn 12, Issue 4, 2010, Pages

  Seeuws, Sylvie ^a   Jacques, Peggy ^a   Van Praet, Jens ^a   Drennan, Michael ^a   Coudenys, Julie ^a   Decruy, Tine ^a   Deschepper, Ellen ^a   Lepescheux, Lien ^b   Pujuguet, Philippe ^b   Oste, Line ^b   Vandeghinste, Nick ^b   Brys, Reginald ^b   Verbruggen, Gust ^a   Elewaut, Dirk ^a  

^a GHENT UNIVERSITY   (Belgium)

^b GALAPAGOS NV   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; COLLAGEN; IMMUNOGLOBULIN G2A ANTIBODY; STROMELYSIN; AUTOANTIBODY; IMMUNOGLOBULIN G;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; BONE EROSION; CARTILAGE DEGENERATION; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; GOLD STANDARD; HISTOLOGY; INFLAMMATION; MALE; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; TISSUE INJURY; VALIDATION PROCESS; X RAY; ANIMAL; BLOOD; BONE; CARTILAGE; DBA MOUSE; DISEASE COURSE; DISEASE MODEL; IMMUNOLOGY; METABOLISM; METHODOLOGY; RADIOGRAPHY; REGRESSION ANALYSIS;

ANIMALS; ARTHRITIS, EXPERIMENTAL; AUTOANTIBODIES; BIOLOGICAL MARKERS; BONE AND BONES; CARTILAGE; COLLAGEN; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; IMMUNOGLOBULIN G; MALE; MATRIX METALLOPROTEINASE 3; MICE; MICE, INBRED DBA; REGRESSION ANALYSIS; X-RAY MICROTOMOGRAPHY;

EID: 77955839399     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3119     Document Type: Article

References (24)

1. Williams RO. Collagen-induced arthritis in mice. Methods Mol Med 2007, 136:191-199. full_text, 17983149.
2. Boini S, Guillemin F. Radiographic scoring methods as outcome measures in rheumatoid arthritis: properties and advantages. Ann Rheum Dis 2001, 60:817-827. 1753828, 11502606.
3. Larsen A. How to apply Larsen score in evaluating radiographs of rheumatoid arthritis in long-term studies. J Rheumatol 1995, 22:1974-1975.
4. Vermeirsch H, Nuydens RM, Salmon PL, Meert TF. Bone cancer pain model in mice: evaluation of pain behavior, bone destruction and morphine sensitivity. Pharmacol Biochem Behav 2004, 79:243-251. 10.1016/j.pbb.2004.07.011, 15501299.
5. Marinova-Mutafchieva L, Williams RO, Mason LJ, Mauri C, Feldmann M, Maini RN. Dynamics of proinflammatory cytokine expression in the joints of mice with collagen-induced arthritis (CIA). Clin Exp Immunol 1997, 107:507-512. 10.1046/j.1365-2249.1997.2901181.x, 9067525.
6. Larsson E, Erlandsson Harris H, Larsson A, Mansson B, Saxne T, Klareskog L. Corticosteroid treatment of experimental arthritis retards cartilage destruction as determined by histology and serum COMP. Rheumatology (Oxford) 2004, 43:428-434. 10.1093/rheumatology/keh073, 15024132.
7. Oestergaard S, Chouinard L, Doyle N, Karsdal MA, Smith SY, Qvist P, Tanko LB. The utility of measuring C-terminal telopeptides of collagen type II (CTX-II) in serum and synovial fluid samples for estimation of articular cartilage status in experimental models of destructive joint diseases. Osteoarthritis Cartilage 2006, 14:670-679. 10.1016/j.joca.2006.01.004, 16500121.
8. Cho YG, Cho ML, Min SY, Kim HY. Type II collagen autoimmunity in a mouse model of human rheumatoid arthritis. Autoimmun Rev 2007, 7:65-70. 10.1016/j.autrev.2007.08.001, 17967728.
9. Coppieters K, Dreier T, Silence K, de Haard H, Lauwereys M, Casteels P, Beirnaert E, Jonckheere H, Van de Wiele C, Staelens L, Hostens J, Revets H, Remaut E, Elewaut D, Rottiers P. Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis. Arthritis Rheum 2006, 54:1856-1866. 10.1002/art.21827, 16736523.
10. Yoshihara Y, Obata K, Fujimoto N, Yamashita K, Hayakawa T, Shimmei M. Increased levels of stromelysin-1 and tissue inhibitor of metalloproteinases-1 in sera from patients with rheumatoid arthritis. Arthritis Rheum 1995, 38:969-975. 10.1002/art.1780380713, 7612046.
11. Tchetverikov I, Ronday HK, Van El B, Kiers GH, Verzijl N, TeKoppele JM, Huizinga TW, DeGroot J, Hanemaaijer R. MMP profile in paired serum and synovial fluid samples of patients with rheumatoid arthritis. Ann Rheum Dis 2004, 63:881-883. 10.1136/ard.2003.013243, 1755080, 15194590.
12. Hasty KA, Reife RA, Kang AH, Stuart JM. The role of stromelysin in the cartilage destruction that accompanies inflammatory arthritis. Arthritis Rheum 1990, 33:388-397. 10.1002/art.1780330312, 2156511.
13. Ribbens C, Martin y Porras M, Franchimont N, Kaiser MJ, Jaspar JM, Damas P, Houssiau FA, Malaise MG. Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. Ann Rheum Dis 2002, 61:161-166. 10.1136/ard.61.2.161, 1753989, 11796404.
14. Cheung NT, Dawes PT, Poulton KV, Ollier WE, Taylor DJ, Mattey DL. High serum levels of pro-matrix metalloproteinase-3 are associated with greater radiographic damage and the presence of the shared epitope in patients with rheumatoid arthritis. J Rheumatol 2000, 27:882-887.
15. Yamanaka H, Matsuda Y, Tanaka M, Sendo W, Nakajima H, Taniguchi A, Kamatani N. Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis. Arthritis Rheum 2000, 43:852-858. 10.1002/1529-0131(200004)43:4<852::AID-ANR16>3.0.CO;2-7, 10765930.
16. Young-Min S, Cawston T, Marshall N, Coady D, Christgau S, Saxne T, Robins S, Griffiths I. Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers. Arthritis Rheum 2007, 56:3236-3247. 10.1002/art.22923, 17907159.
17. Manicourt DH, Fujimoto N, Obata K, Thonar EJ. Levels of circulating collagenase, stromelysin-1, and tissue inhibitor of matrix metalloproteinases 1 in patients with rheumatoid arthritis. Relationship to serum levels of antigenic keratan sulfate and systemic parameters of inflammation. Arthritis Rheum 1995, 38:1031-1039. 10.1002/art.1780380803, 7639798.
18. So A, Chamot AM, Peclat V, Gerster JC. Serum MMP-3 in rheumatoid arthritis: correlation with systemic inflammation but not with erosive status. Rheumatology (Oxford) 1999, 38:407-410. 10.1093/rheumatology/38.5.407, 10371277.
19. Kim WU, Yoo WH, Park W, Kang YM, Kim SI, Park JH, Lee SS, Joo YS, Min JK, Hong YS, Lee SH, Park SH, Cho CS, Kim HY. IgG antibodies to type II collagen reflect inflammatory activity in patients with rheumatoid arthritis. J Rheumatol 2000, 27:575-581.
20. Brand DD, Kang AH, Rosloniec EF. Immunopathogenesis of collagen arthritis. Springer Semin Immunopathol 2003, 25:3-18. 10.1007/s00281-003-0127-1, 12904888.
21. Watson WC, Townes AS. Genetic susceptibility to murine collagen II autoimmune arthritis. Proposed relationship to the IgG2 autoantibody subclass response, complement C5, major histocompatibility complex (MHC) and non-MHC loci. J Exp Med 1985, 162:1878-1891. 10.1084/jem.162.6.1878, 2187982, 3934318.
22. Nishida S, Tsurukami H, Sakai A, Sakata T, Ikeda S, Tanaka M, Ito M, Nakamura T. Stage-dependent changes in trabecular bone turnover and osteogenic capacity of marrow cells during development of type II collagen-induced arthritis in mice. Bone 2002, 30:872-879. 10.1016/S8756-3282(02)00725-1, 12052456.
23. Noguchi M, Kimoto A, Sasamata M, Miyata K. Micro-CT imaging analysis for the effect of celecoxib, a cyclooxygenase-2 inhibitor, on inflammatory bone destruction in adjuvant arthritis rats. J Bone Miner Metab 2008, 26:461-468.
24. Gravallese EM. Bone destruction in arthritis. Ann Rheum Dis 2002, 61(Suppl 2):ii84-86. 1766721, 12379632.